This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the BOSULIF®▼ (bosutinib) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BOSULIF Prescribing Information for Great Britain and for Northern Ireland, and adverse event reporting information can be found at the bottom of the page.

New challenges: long-term TKI therapy in an ageing patient population video

​​​​​​​Speaker: Dr Alex Lyon

Duration: 5.14

In this video, Alex discusses his role as a Cardiologist in managing CML patients on a TKI (Tyrosine Kinase Inhibitor).  He reviews patients before, during and after treatment working in close communication and collaboration with the multi-disciplinary team with the underlying goal of keeping patients on treatment for as long as possible whilst minimising cardiovascular disease. He discusses recommended tests and interventions as well risk factors to be aware of.​​

Dr. Alex Lyon is a Senior Lecturer in Cardiology at Imperial College, London and a Consultant Cardiologist at the Royal Brompton Hospital. Alex has been the Clinical Lead for the cardio-oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment.
​​​​​​​
His clinical interests are in the fields of heart failure, cardio-oncology including chemotherapy cardiomyopathy and the cardiovascular complications of modern cancer therapies, Takotsubo syndrome and the effects of major stresses of the heart and the development of novel therapeutics including gene therapy for chronic heart failure.  Alex has published 111 scientific papers in peer-reviewed journals and several book chapters in cardiovascular textbooks; he is an Associate Editor of the European Journal of Heart Failure.

Explore more

Review ELN Guidelines

Compare 2013 guidelines to those published in 2020

Explore more

TKIs in CML

Watch Prof. Richard Clark discuss the holistic approach to treatment decisions for patient with CML

Learn more on TKIs in CML


This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
PP-BOS-GBR-1310. September 2021

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

Read the latest guidance

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

Learn more


  • For UK Healthcare Professionals*

    These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

    I confirm that I am a healthcare professional* resident in the United Kingdom.

    If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

    *The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

    PP-PFE-GBR-2688. December 2020

    Yes

    No